1-{3-[(2-([1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]oxy)ethyl)oxy}phenyl]methanamine → 5,6-difluoro-4-oxo-N-({3-[(2-{[1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]oxy}ethyl)oxy]phenyl}methyl)-3,4-dihydroquinazoline-2-carboxamide

HRID 606403ノート

反応式

HRID 606403 の反応式
[C:1]1([C:7]([C:31]2[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=2)([C:25]2[CH:30]=[CH:29][CH:28]=[CH:27][CH:26]=2)[N:8]2[CH:12]=[N:11][C:10]([O:13][CH2:14][CH2:15][O:16][C:17]3[CH:18]=[C:19]([CH2:23][NH2:24])[CH:20]=[CH:21][CH:22]=3)=[N:9]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[F:37][C:38]1[C:47]([F:48])=[CH:46][CH:45]=[C:44]2[C:39]=1[C:40](=[O:54])[NH:41][C:42]([C:49](OCC)=[O:50])=[N:43]2>C(O)C>[F:37][C:38]1[C:47]([F:48])=[CH:46][CH:45]=[C:44]2[C:39]=1[C:40](=[O:54])[NH:41][C:42]([C:49]([NH:24][CH2:23][C:19]1[CH:20]=[CH:21][CH:22]=[C:17]([O:16][CH2:15][CH2:14][O:13][C:10]3[N:11]=[CH:12][N:8]([C:7]([C:1]4[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=4)([C:25]4[CH:26]=[CH:27][CH:28]=[CH:29][CH:30]=4)[C:31]4[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=4)[N:9]=3)[CH:18]=1)=[O:50])=[N:43]2

参加物

4

反応物 2

HCID 667690991-{3-[(2-([1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]oxy)ethyl)oxy}phenyl]methanamineHCID 136029322Ethyl 5,6-difluoro-4-oxo-3,4-dihydroquinazoline-2-carboxylate

生成物 1

HCID 1363809705,6-difluoro-4-oxo-N-({3-[(2-{[1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]oxy}ethyl)oxy]phenyl}methyl)-3,4-dihydroquinazoline-2-carboxamide収率 41%

試薬・触媒・溶媒 1

HCID 702Ethanol溶媒

反応条件

温度
80 °C

実験手順

A suspension of 1-{3-[(2-{[1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]oxy]ethyl)oxy}phenyl}methanamine obtained in Reference Example 32 (300 mg, 1.18 mmol) and ethyl 5,6-difluoro-4-oxo-3,4-dihydroquinazoline-2-carboxylate obtained in Reference Example 57 (562 mg, 1.18 mmol) in ethanol (10 mL) was stirred at 80° C. for 12 hr. The insoluble material was filtered off hot, and the filtrate was allowed to cool to room temperature. The precipitated solid was collected by filtration using glass filter, and the obtained solid was washed with diethyl ether to give 5,6-difluoro-4-oxo-N-({3-[(2-{[1-(triphenylmethyl)-1H-1,2,4-triazol-3-yl]oxy}ethyl)oxy]phenyl}methyl)-3,4-dihydroquinazoline-2-carboxamide as a pale-yellow powder (330 mg, 41%).

後処理

  1. filtrationThe insoluble material was filtered off hot
  2. temperatureto cool to room temperature
  3. filtrationThe precipitated solid was collected by filtration
  4. filtrationfilter
  5. washthe obtained solid was washed with diethyl ether

出典と根拠

ORDレコード
ord-6155de3ef4504fd9a218d806ba86b3aa
出典データセット
uspto-grants-2011_03
特許番号
US07915267B2

反応ノート

読み込み中…